Abstract
The purpose of this presentation is to increase nursing awareness of a new treatment option available for Chronic Lymphocytic Leukemia (CLL) patients. In 2010, a new treatment module was developed for CLL patients with the goal of sustained remissions. This new treatment option called: Chimeric Antigen Receptor T-cells therapy (CART-19) are laboratory created T-cells (white blood cells) that have the ability to target the CD19 antigens found on all B-cell malignant tumors (Porter, 2013). Currently, this treatment option is only received in a clinical trial; however, these patients can have serious adverse reactions causing them to seek management in the emergency department. There is a nursing knowledge and skill deficit related to this treatment option. Therefore, formal education is warranted in order to increase awareness and promote health literacy.
Sigma Membership
Unknown
Lead Author Affiliation
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
Type
Poster
Format Type
Text-based Document
Study Design/Type
N/A
Research Approach
Quantitative Research
Keywords:
Chimeric Antigen Receptor T-cells therapy (CART-19), Chronic Lymphocytic Leukemia, Cytokine Release Syndrome
Recommended Citation
Morrison, Felicia M., "Treatment options for chronic lymphocytic leukemia tumors chimeric antigen receptor modified T cells therapy (CART-19)" (2017). INRC (Congress). 12.
https://www.sigmarepository.org/inrc/2017/posters_2017/12
Conference Name
28th International Nursing Research Congress
Conference Host
Sigma Theta Tau International
Conference Location
Dublin, Ireland
Conference Year
2017
Rights Holder
All rights reserved by the author(s) and/or publisher(s) listed in this item record unless relinquished in whole or part by a rights notation or a Creative Commons License present in this item record.
All permission requests should be directed accordingly and not to the Sigma Repository.
All submitting authors or publishers have affirmed that when using material in their work where they do not own copyright, they have obtained permission of the copyright holder prior to submission and the rights holder has been acknowledged as necessary.
Acquisition
Proxy-submission
Treatment options for chronic lymphocytic leukemia tumors chimeric antigen receptor modified T cells therapy (CART-19)
Dublin, Ireland
The purpose of this presentation is to increase nursing awareness of a new treatment option available for Chronic Lymphocytic Leukemia (CLL) patients. In 2010, a new treatment module was developed for CLL patients with the goal of sustained remissions. This new treatment option called: Chimeric Antigen Receptor T-cells therapy (CART-19) are laboratory created T-cells (white blood cells) that have the ability to target the CD19 antigens found on all B-cell malignant tumors (Porter, 2013). Currently, this treatment option is only received in a clinical trial; however, these patients can have serious adverse reactions causing them to seek management in the emergency department. There is a nursing knowledge and skill deficit related to this treatment option. Therefore, formal education is warranted in order to increase awareness and promote health literacy.